Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial

Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Propolis i...

Full description

Bibliographic Details
Main Authors: Marcelo Augusto Duarte Silveira, David De Jong, Andresa Aparecida Berretta, Erica Batista dos Santos Galvão, Juliana Caldas Ribeiro, Thiago Cerqueira-Silva, Thais Chaves Amorim, Luis Filipe Miranda Rebelo da Conceição, Marcel Miranda Dantas Gomes, Maurício Brito Teixeira, Sergio Pinto de Souza, Marcele Helena Celestino Alves dos Santos, Raissa Lanna Araújo San Martin, Márcio de Oliveira Silva, Monique Lírio, Lis Moreno, Julio Cezar Miranda Sampaio, Renata Mendonça, Silviana Salles Ultchak, Fabio Santos Amorim, João Gabriel Rosa Ramos, Paulo Benigno Pena Batista, Suzete Nascimento Farias da Guarda, Ana Verena Almeida Mendes, Rogerio da Hora Passos
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Propolis
Anti-inflammatory agents
Immunoregulation
ACE2
PAK1 blocker
TMPRSS2
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221003115

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221003115

Similar Items